Vaccine therapy for cancer - Fact or fiction?

QJM: An International Journal of Medicine

Volumn 92, Issue 6, 1999, Pages 299-307

  Evans, T R J ^a,b   Kaye, S B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Garscube Estate   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; GENE PRODUCT; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; IMMUNITY; ONCOGENE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUPPRESSOR GENE;

EID: 0033032865     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/92.6.299     Document Type: Review

References (117)

1. Coley WB. The treatment of malignant tumours by repeated inoculations of erysipolas; with a report of ten original cases. Am J Med Sci 1893; 105:487-511.
2. Nauts HC. Bacteria and Cancer - antagonisms and benefits. Cancer Surv 1989; 8:713-23.
3. Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H. Mechanisms of syngeneic tumor-rejection. Susceptibility of host selected progressor variants to various immunological effector cells. J Exp Med 1982; 155:557-73.
4. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytome P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983; 157:1040-52.
5. Wortzel RD, Philipps C, Schreiber H. Multiple tumour-specific antigens expressed on a single tumour cell. Nature 1983; 304:165-7.
6. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 1984; 311:750-2.
7. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2k antigens following H-2-gene transfection. Nature 1985; 315:301-5.
8. Haywood GR, McKhann CF. Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity. J Exp Med 1971; 133:1171-87.
9. Trowsdale J, Travers P, Bodmer WF, Patillo RA. Expression of HLA-A, -B, and -C and beta 2-microglobulin antigens in human choriocarcinoma cell lines. J Exp Med 1980; 152:11s-17s.
10. Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennink JR, Mule JJ, Yewdell JW, Rosenberg SA. Defective presentation of endogenous antigen by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol 1991; 147:1453-9.
11. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87:1486-90.
12. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J-C, Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274:1363-6.
13. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H. Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991; 65:305-17.
14. Burkly LC, Lo D, Kanagawa O, Brinster RL, Flavell RA. T-cell tolerance by clonal energy in transgenic mice with nonlymphoid expression of MHC class II I-E. Nature 1989; 342:564-6.
15. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95:1178-83.
16. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997; 186:229-38.
17. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS. Self antigens expressed by solid tumors do not efficiently stimulate naïve or activated T-cells: Implications for immunotherapy. J Exp Med 1997; 186:645-53.
18. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann Rev Immunol 1989; 7:445-80.
19. Schwartz RH. Acquisition of immunological self-tolerance. Cell 1989; 57:1073-81.
20. Schwartz RH. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065-8.
21. Broder S, Waldmann TA. The suppressor-cell network in cancer (first of two parts). N Engl J Med 1978; 299:1281-4.
22. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alternations in signal transduction molecules in T-lymphocytes from tumor-bearing mice. Science 1992; 258:1795-8.
23. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, Finke JH. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin-2 and express interleukin-2 receptors. Cancer Res 1993; 53:1380-7.
24. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53:5613-16.
25. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivier E, Anderson P, Kiessling R. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53:5610-12.
26. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, D'Enghein CD, Lee R, Debree B, Fridman WH. Variable expression of CD3-ζ chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 1995; 63:205-12.
27. Renner C, Ohnesorge S, Held C, Bauer S, Jung W, Pfitzenmeier J-P, Pfreundschuh M. T-cells from patients with Hodgkin's disease have a defective T-cell receptor ζ chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 1996; 88:236-41.
28. INk4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281-4.
29. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997; 275:1790-2.
30. Huang AYC, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee EM. The immunodominant major histocompatability complex class 1-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 1996; 93:9730-5.
31. van der Bruggen P, Traversari C, Chomez P, Lurquin C, de Plaen E, van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-6.
32. Chen Y-T, Stockert E, Chen Y, Garin-Chesa P, Rettig W, van der Bruggen P, Boon T, Old LJ. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA 1994; 91:1004-8.
33. Gaugler B, van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, dePlaen E, Lethe B, Brasseur F, Boon T. Human gene MAGE-3 codes for an antigen recognised on a melanoma by antologous cytolytic T lymphocytes. J Exp Med 1994; 179:921-30.
34. + T cells specifically recognise a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91:9461-5.
35. Brichard V, van Pel A, Wolfel T, Wolfel C, de Plaen E, Lethe B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by antologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178:489-95.
36. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264:716-19.
37. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91:6458-62.
38. Bos JL. ras oncogenes in human cancer: A review. Cancer Res 1989; 49:4682-9.
39. Barbacid M. ras genes. Ann Rev Biochem 1987; 56:779-827.
40. Jung S, Schluesener JH. Human T lymphocytes recognise a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991; 173:273-6.
41. + T cells recognise a peptide corresponding to a common mutation (13 Gly→Asp). Int J Cancer 1994; 56:40-5.
42. Gedde-Dahl III T, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G. Memory T cells of a patient with follicular thyroid carcinoma recognise peptides derived from mutated p21 ras (Gln→Leu 61). Int Immunol 1992; 4:1331-7.
43. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351:453-6.
44. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991; 253:49-53.
45. + cytotoxic T-cells. Cancer Res 1993; 53:3257-61.
46. + T cells. Proc Natl Acad Sci USA 1994; 91:3171-5.
47. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ. P53 as a target for cancer vaccines: Recombant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996; 93:4781-6.
48. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.
49. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkorski M, Akita R, Paterson MC, Slamon DJ. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53:4960-70.
50. Brossart P, Stuhler G, Flad T, Steanovic S, Rammensee H-G, Kanz L, Brugger W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognised by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58:732-6.
51. -neu receptor. Nature Med 1995; 1:644-8.
52. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 1981; 2:1129-33.
53. Larouze B, Saimot G, Lustbader ED, London WT, Werner BG, Payet M. Host response to hepatitis-B infection in patients with primary hepatic carcinoma and their families: a case/control study in Senegal, West Africa. Lancet 1976; 2:534-8.
54. Brechet C, Hadchouel M, Scotto J, Degos F, Charnay P, Trepo C, Tiollais P. Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet 1981; 2:765-8.
55. Chang M-H, Chen C-J, Lai M-S, Hsu H-M, Wu T-C, Kong M-S, Liang D-C, Shan W-Y, Chen D-S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336:1855-9.
56. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt RMP, Hartman M, Anholts JDH, Schreuder GMT, Bram ter Harmsel W, Fleuren GJ, Trimbos BJ, Kast WM, Melief CJM. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A 0201-restricted E7-encoded epitope. Cancer Res 1996; 56:582-8.
57. de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JMM, Remmink AJ, Verheijen RHM, Helmerhorst TJ, Meijer CJ, Scheper RJ. T-cell proliferative responses against human papiollomavirus type 16 E7 oncoprotein are most prominent in cervical intra-epithelial neoplasia patients with a persistent viral infection. J Gen Virol 1996; 77:2183-91.
58. Berd D, Maguire HC, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8:1858-67.
59. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogenic lysates and a novel adjuvant. Cancer Res 1988; 48:5883-93.
60. Tepper RI, Mule JJ. Review: Experimental and clinical studies of cytokine gene-modified tumor cells. Human Gene Ther 1994; 5:153-64.
61. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-43.
62. Banchereau K, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
63. + T cells by B7-transfected melanoma cells. Science 1993; 259:368-70.
64. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71:1093-102.
65. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179:523-32.
66. Boussiotis VA, Freeman G, Gray G, Gribben J, Nadler FM. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993; 178:1753-63.
67. Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993; 262:905-7.
68. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB, Gray GS, Nadler LM, Sharpe AH. Uncovering of functional alternative CTLA-4 counter-receptor in B-7 deficient mice. Science 1993; 262:907-9.
69. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray GS, Nadler LM. Cloning of B7-2: A CTLA-4 counter receptor that costimulates human T cell proliferation. Science 1993; 262:909-11.
70. Tanaka K, Hayashi H, Hamada C, Khoury G, Jay G. Expression of major histocompatability complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci USA 1986; 83:8723-7.
71. b gene. Proc Natl Acad Sci USA 1988; 85:4463-7.
72. Gelber C, Plaksin D, Vadai E, Feldman M, Eisenbach L. Abolishment of metastasis formation by murine tumor cells transfected with 'foreign' H-2K genes. Cancer Res 1989; 49:2366-73.
73. b gene transfection. J Immunol 1993; 151:3467-77.
74. Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990; 144:4068-71.
75. Ostrand-Rosenberg S, Roby C, Clements VK, Cole GA. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class II genes or allogenic MHC-class I genes. Int J Cancer 1991; 48(suppl 6):61-8.
76. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264:961-5.
77. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Casanelli N, Bourland A, Vanwijck R, Humblet Y, Canon J-L, Laurent C, Naeyaert J-M, Plagne R, Deraemaeker R, Knuth A, Jager E, Brasseur F, Herman J, Coulio PG, Boon T. Tumor regression in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63:883-5.
78. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998; 4:321-7.
79. Aichele P, Brduscha-Riem K, Zinkernagel RM, Hengartner H, Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 1995; 182:261-6.
80. Toes RE, Blom RJ, Offinga R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 1996; 156:3911-18.
81. Lathe R, Kieny MP, Gerlinger P, Clertant P, Guizani I, Cuzni F, Chambon P. Tumor prevention and rejection with recombinant vaccinia. Nature 1987; 326:878-80.
82. Moss B, Smith GL, Gerin JI, Purcell RH. Live recombinant vacania virus protects chimpanzees against hepatitis B. Nature 1984; 311:67-9.
83. Bernards R, Destree A, McKenzie S, Gordon E, Weinberg RA, Panicali D. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sd USA 1987; 84:6854-8.
84. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 1996; 156:224-31.
85. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995; 154:4685-92.
86. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunised with recombinant vaccinia - CEA vaccine. J Natl Cancer Inst 1995; 87:982-90.
87. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GWG, Westmoreland D, Evans AS, Adams M, Stacey SN, Bourrnell MEG, Rutherford E, Hickling JK, Inglis SC. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347:1523-7.
88. Hoiseth SK, Stocker BAD. Aromatic-dependent salmonella typhimirium are non-virulent and effective as live vaccines. Nature 1981; 291:238-9.
89. Sadoff JC, Ballou WR, Baron LS, Majarian WR, Brey RN, Hockmeyer WT, Young JF, Cryz SJ, Ou J, Lowell GH, Chulay JD. Oral salmonella typhimirium vaccine expressing circumsporozoite protein protects against malaria. Science 1988; 240:336-8.
90. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF, Snapper SB, Barletta RG, Jacobs WR, Bloom BR. New use of BCG for recombinant vaccines. Nature 1991; 351:456-60.
91. Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 1991; 351:479-82.
92. Schafer R, Portnoy DA, Brassell SA, Paterson Y. Induction of a cellular immune response to a foreign antigen by a recombinant listeria monocytogenes vaccine. J Immunol 1992; 149:53-9.
93. Pan Z-K, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Med 1995; 1:471-7.
94. Pan Z-K, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumours in mice mediated by the oral administration of a recombinant listeria monocytogenes vaccine. Cancer Res 1995; 55:4776-9.
95. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Feigner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8.
96. Tang D, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356:152-4.
97. Ulmer JB, Donelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiver JW, Montgomery DL, Liu MA. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9.
98. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997; 89:1595-601.
99. Roz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA, Baird SM, Rhodes GH. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc. Natl Acad Sci USA 1994; 91:9519-23.
100. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunization by parenteral, mucosal and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90:11478-82.
101. Nabel GJ, Nabel EG, Yang Z-Y, Fox BA, Plantz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90:11307-11.
102. Jones DH, Corris S, McDonald S, Clegg JCS, Farrar GH. Poly (DL-lactide-co-glycolide) - encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997; 15:814-17.
103. Hersey P, Edwards A, Coates A, Shaw H, McCarthy W, Milton G. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol Immunother 1987; 25:257-65.
104. McGee JM, Lytle GH, Malnar KF, Price JA, Humphrey LJ. Melanoma tumor vaccine: five-year follow-up. J Surg Oncol 1991; 47:233-8.
105. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Dautyan DG, Gupta RK, Elashoff R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216:463-82.
106. Bystryn JC. Clinical activity of a polyvalent melanoma antigen vaccine. Rec Res Cancer Res 1995; 139:337-48.
107. Wallace MK, Sivanandham M, Ditaranto K, Shaw P, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Rosen L, Bartolucci AA. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 1997; 226:198-206.
108. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982-90.
109. McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 1996; 3:495-500.
110. Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96:334-42.
111. Lehner B, Schlag P, Liebrich W, Schirrmacher V. Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus - modified autologous tumour cell vaccine. Cancer Immunol Immunother 1990; 32:173-8.
112. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S-I, Kim YS. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990; 66:1960-6.
113. Miles DW, Linehan J, Smith P, Filipe I. Expression of sialyl-Tn in gastric cancer: correlation with known prognostic factors. Br J Cancer 1995; 71:1074-6.
114. Kobayashi H, Terao T, Kawashima Y. Serum sialyl-Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992; 10:95-101.
115. Miles DW, Happerfield LC, Smith P, Gillibrand R, Bobrow LG, Gregory WM, Rubens RD. Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer 1994; 70:1272-5.
116. MacLean GD, Reddish MA, Koganty RR, Wong T, Gandhi S, Smolenski M, Samuel J, Nabholtz JM, Longenecker BM. Immunisation of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993; 36:215-22.
117. Miles DW, Towlson KE, Graham R, Reddish M, Longenecker BM, Taylor-Papadimitriou J, Rubens RD. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996; 74:1292-6.